EC Number   |
Application |
Reference |
|---|
   3.1.3.48 | diagnostics |
decreased PTPN12 protein level is associated with poor prognosis of several types of cancers |
750513 |
| 3.1.3.48 | drug development |
inhibition of MptpA and MptpB represents a promising strategy for the development of selective antibiotics against this severe pathogen |
707140 |
| 3.1.3.48 | drug development |
MptpB is a promising target for anti-tuberculosis drug development |
710188 |
| 3.1.3.48 | drug development |
MptpB is a promising target for development of anti-tuberculosis drugs |
710432 |
| 3.1.3.48 | drug development |
PTP1B is a target for drug development in treatment of type II diabetes and obesity |
709293 |
| 3.1.3.48 | drug development |
the enzyme is a target for inhibitor design |
709102 |
| 3.1.3.48 | medicine |
homozygous enzyme-deficient animal, hyperresponsive to insulin and leptin and resistant to diet-induced obesity. Liver-specific re-expression of PTP1B leads to marked attenuation of their enhanced insulin sensitivity in correlation with decreased insulin-stimulated tyrosyl phosphorylation of the insulin receptor and insulin receptor substrate 2-associated phosphatidylinositide 3-kinase activity. Preferential dephosphorylation of Y1162/1163 of insulin receptor |
665612 |
| 3.1.3.48 | medicine |
overview on implications with human diseases and as therapeutic targets |
650928 |
| 3.1.3.48 | medicine |
PTP-1B antagonizes insulin signaling and is a potential therapeutic target for insulin resistance associated with obesity and type 2 diabetes |
692092 |
| 3.1.3.48 | medicine |
PTPalpha and PTP1B responsible for counteraction of insulin signaling, LAR and PTPalpha may act upon cell surface insulin receptors |
652081 |
